IRAK1: A novel TOLLway to target ovarian cancer

被引：0
|
作者：
Standing, David [1 ]
Gunewardena, Sumedha [1 ]
Sayed, Afreen A. [1 ]
Pritchard, Michele T. [1 ]
Pathak, Harsh B. [1 ]
Godwin, Andrew K. [1 ]
Petersen, Shariska [1 ]
Khabele, Dineo [2 ]
Roy, Jensen A. [1 ]
Dandawate, Prasad [1 ]
Weir, Scott J. [1 ]
Anant, Shrikant [1 ]
机构：
[1] Univ Kansas, Med Ctr, Kansas City, KS 66103 USA
[2] Siteman Canc Ctr, St Louis, MO USA
来源：
CANCER RESEARCH | 2022年 / 82卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5306
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Inhibition of IRAK1/4 enhances the antitumor effect of lenvatinib in anaplastic thyroid cancer cells
    Kawamura, Yoshifumi
    Saijo, Ken
    Imai, Hiroo
    Ishioka, Chikashi
    CANCER SCIENCE, 2021, 112 (11) : 4711 - 4721
  • [32] miR-146a Enhances the Sensitivity of Breast Cancer Cells to Paclitaxel by Downregulating IRAK1
    Li, Yalun
    Li, Weilong
    Lin, Jun
    Lv, Chunjing
    Qiao, Guangdong
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2022, 37 (08) : 624 - 635
  • [33] IRAK1, a Target of miR-146b, Reduces Cell Aggressiveness of Human Papillary Thyroid Carcinoma
    Chou, Chen-Kai
    Chi, Shun-Yu
    Huang, Cai-Hua
    Chou, Fong-Fu
    Huang, Chao-Cheng
    Liu, Rue-Tsuan
    Kang, Hong-Yo
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2016, 101 (11): : 4357 - 4366
  • [34] IRAK1 is a critical mediator of hyaluronic acid induced stemness
    Standing, David
    Dandawate, Prasad
    Johnson, Jaimie
    Gunewardena, Sumedha
    Pritchard, Michele T.
    Pathak, Harsh
    Khabele, Dineo
    Roby, Katherine
    Godwin, Andrew
    Jensen, Roy
    Weir, Scott
    Anant, Shrikant
    CANCER RESEARCH, 2023, 83 (07)
  • [35] Inhibition of IRAK1 Is an Effective Therapy for Autoimmune Hypophysitis in Mice
    Huang, Hsiao-Chen
    Chen, Yun-Ti
    Lin, Han-Huei
    Li, Zhi-Qin
    Yang, Jinn-Moon
    Tzou, Shey-Cherng
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (23)
  • [36] SPHK1 Is a Novel Target of Metformin in Ovarian Cancer
    Hart, Peter C.
    Chiyoda, Tatsuyuki
    Liu, Xiaojing
    Weigert, Melanie
    Curtis, Marion
    Chiang, Chun-Yi
    Loth, Rachel
    Lastra, Ricardo
    McGregor, Stephanie M.
    Locasale, Jason W.
    Lengyel, Ernst
    Romero, Iris L.
    MOLECULAR CANCER RESEARCH, 2019, 17 (04) : 870 - 881
  • [37] The mechanism of activation of IRAK1 and IRAK4 by interleukin-1 and Toll-like receptor agonists
    Vollmer, Stefan
    Strickson, Sam
    Zhang, Tinghu
    Gray, Nathanael
    Lee, Katherine L.
    Rao, Vikram R.
    Cohen, Philip
    BIOCHEMICAL JOURNAL, 2017, 474 : 2027 - 2038
  • [38] Novel target for ovarian cancer immunotherapy
    Saed, G. M.
    Fletcher, N. M.
    Memaj, I.
    Saed, M. G.
    Diamond, M. P.
    Morris, R. T.
    GYNECOLOGIC ONCOLOGY, 2017, 145 : 38 - 38
  • [39] Sequential control of Toll-like receptor–dependent responses by IRAK1 and IRAK2
    Tatsukata Kawagoe
    Shintaro Sato
    Kazufumi Matsushita
    Hiroki Kato
    Kosuke Matsui
    Yutaro Kumagai
    Tatsuya Saitoh
    Taro Kawai
    Osamu Takeuchi
    Shizuo Akira
    Nature Immunology, 2008, 9 : 684 - 691
  • [40] Upregulated IL-1 receptor-associated kinase 1 (IRAK1) in systemic lupus erythematosus: IRAK1 inhibition represses Th17 differentiation with therapeutic potential
    Zhong, Z.
    Ni, B.
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2019, 49 : 950 - 950
12345